Cognitive impairment is common among older adults hospitalized for non-neurological conditions but often goes unrecognized, particularly in rehabilitation settings where clinical attention is mainly focused on physical recovery. The COGinREHAB study is a multicenter, prospective, longitudinal interventional study conducted at three rehabilitation centers of the Fondazione Don Carlo Gnocchi in Italy (Florence and Milan).
The study will enroll 384 patients aged 45 years or older who are hospitalized for at least 7-10 days in cardiac, pulmonary, or orthopedic intensive rehabilitation units, or in intermediate care units, for conditions unrelated to the nervous system.
At admission, all participants undergo a clinical and cognitive screening visit. Patients whose screening results suggest possible cognitive impairment then undergo a more extensive neuropsychological evaluation. In those with confirmed cognitive impairment, additional blood tests are performed to measure biomarkers of neurodegeneration (GFAP, neurofilament light chain, and phosphorylated tau-217), together with APOE genotyping and a non-contrast brain CT scan. In a subset of these patients, resting-state EEG, auditory event-related potentials, actigraphy, and overnight polysomnography are also performed. Patients with confirmed cognitive impairment are invited to a follow-up visit 12 months later to assess whether their cognitive profiles and biological markers have changed.
The main purpose of the study is to estimate how frequently cognitive impairment occurs among patients admitted to non-neurological rehabilitation units, including how often it was previously undiagnosed. The study will also describe the clinical, biological, and neurophysiological profile of these patients and examine how cognitive impairment evolves over one year.
Inclusion Criteria:
Exclusion Criteria:
crpolito@dongnocchi.it+390557393653
Hospitalized patients aged ≥45 years admitted to cardiac, pulmonary, or orthopedic intensive rehabilitation units, or intermediate care units, for non-neurological conditions. All participants undergo a baseline clinical and cognitive screening visit (T0). Participants whose screening results suggest cognitive impairment undergo an extended neuropsychological assessment; those in whom cognitive impairment is confirmed additionally undergo blood sampling for APOE genotyping and plasma biomarkers of neurodegeneration (GFAP, NfL, pTau-217), a non-contrast brain CT scan, and, in a subset, multimodal neurophysiological assessment (resting-state EEG, auditory P300, actigraphy, polysomnography). Participants with confirmed cognitive impairment at T0 are re-assessed at a 12-month follow-up visit (T1).
ctu@DONGNOCCHI.IT+390557393653
Florence, FI 50143, Italy
crpolito@dongnocchi.it+390557393653
ptrimarchi@DONGNOCCHI.IT+390557393653
agallucci@dongnocchi.it+390557393653
Exercises for Rehabilitation of COgnition and Lifestyle Enhancement in Patients With Mild Cognitive Impairment
EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069
Multidimensional Rehabilitation Programs for Cognitive Impairment in Comorbid Outpatients: a Randomized Controlled Trial
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline
Improving the Referral of Patients With Suspected Cognitive Impairment and Early Dementia
Prediction, Prevention, Predisposition: Applications in Neurology and Endocrinology
Dementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms.